Physician profile
Emmanuel Javier
NPI 1740283779
$492.56
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $169 · 2020: $98.63 · 2021: $16.49 · 2022: $31.63 · 2023: $105 · 2024: $72.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $177.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $64.69 | 2019-2020 | |
| Amgen INC. | $61.78 | 2019-2024 | Evenity, Prolia |
| Merck Sharp & Dohme LLC | $53.82 | 2019 | |
| Dexcom, INC. | $52.02 | 2021-2023 | Dexcom G6 Transmitter |
| Medtronic, INC. | $37.71 | 2023 | Minimed 780g |
| Abbott Laboratories | $37.18 | 2020-2022 | |
| Lilly USA, LLC | $31.00 | 2019-2024 | Jardiance, Zepbound |
| Lexicon Pharmaceuticals, INC. | $20.56 | 2023 | Inpefa |
| Eisai INC. | $20.40 | 2019 | |
| Companion Medical, INC. | $18.10 | 2020 | |
| Insulet Corporation | $17.65 | 2024 | Omnipod |
| Cequr Corporation | $15.50 | 2024 | Cequr Simplicity |
| Horizon Therapeutics Plc | $15.02 | 2020 | |
| Antares Pharma, INC. | $12.43 | 2019 | |
| Xeris Pharmaceuticals, INC. | $12.33 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.44 | 2019 | |
| Beta Bionics, INC. | $10.93 | 2023 | Ilet Bionic Pancreas |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emmanuel Javier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.